

July 22, 2022

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001

Ref: Scrip Code: 543322

Dear Sirs,

To,
The Manager – Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Name: GLS

Sub:- Board Meeting

We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Thursday, August 4, 2022, inter alia, to consider and approve the Unaudited Financial Results of the Company for the first quarter ended June 30, 2022.

Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from June 30, 2022 to August 6, 2022 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the first quarter ended June 30, 2022.

The above is for your information.

Thanking you.

Yours faithfully,

For Glenmark Life Sciences Limited

Rudalf Corriea

Company Secretary & Compliance Officer